Angiosarcoma developing after curative induction chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the larynx

Head Neck. 2009 Jun;31(6):829-32. doi: 10.1002/hed.20929.

Abstract

Background: Angiosarcoma arising after radiation is described in breast cancer but occurs elsewhere. Here, we present an angiosarcoma of the neck occurring after curative chemoradiation.

Methods: This is a case of angiosarcoma developing 5 years after curative therapy for T3N0 squamous cell carcinoma of the supraglottic larynx. Therapy consisted of 3 cycles of induction cisplatin/5-fluorouracil chemotherapy followed by radiotherapy. The patient did well until developing a rapidly progressive lesion of the left neck. Examination showed a 7-cm mass and biopsy revealed angiosarcoma. CT scans assessed the local extent of the tumor and ruled out metastatic disease prior to initiating therapy.

Results: Therapy consisted of 4 cycles of paclitaxel chemotherapy. At completion, examination revealed mild induration of the neck with near-complete resolution of the mass. Imaging confirmed this excellent response.

Conclusion: This rare therapy-related second malignancy developed after curative larynx-preserving treatment. Paclitaxel was an effective therapy in this setting.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Biopsy, Needle
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / therapy*
  • Follow-Up Studies
  • Hemangiosarcoma / drug therapy
  • Hemangiosarcoma / etiology*
  • Hemangiosarcoma / pathology
  • Humans
  • Immunohistochemistry
  • Laryngeal Neoplasms / pathology
  • Laryngeal Neoplasms / therapy*
  • Male
  • Neoplasm Invasiveness / pathology
  • Neoplasm Staging
  • Paclitaxel / administration & dosage
  • Radiotherapy, High-Energy / adverse effects*
  • Radiotherapy, High-Energy / methods
  • Remission Induction
  • Risk Assessment
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / etiology*
  • Skin Neoplasms / pathology
  • Treatment Outcome

Substances

  • Paclitaxel